FDA approves a new, longer-acting version of the antidepressant bupropion.

The U.S. Food and Drug Administration (FDA) has approved a new, extended-release tablet form of the antidepressant medicine bupropion. This medicine is approved to treat major depressive disorder in adults. It is a sustained-release version, which means the medicine is released slowly into the body over the course of a day. This is not a brand-new type of drug, but a new formulation of a medicine that has been used for many years. The approval is based on studies in adults that showed the drug's effectiveness over several weeks of treatment. The FDA label also includes information supporting its use for longer-term maintenance of treatment response for patients who benefit from it initially. This provides doctors with another option for managing depression over an extended period. It's important to know that the approval does not mean this drug is a cure or is right for every person with depression. Like all medicines, it has potential side effects and risks, which are described in its official prescribing information. The most important step for anyone considering a new treatment is to have a detailed conversation with their doctor. A doctor can help determine if this specific medication is a suitable choice based on an individual's health history and needs.